BiotechTube

Daptomycin + Vancomycin + Teicoplanin

Phase 3Terminated
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Skin Diseases, Infectious

Conditions

Skin Diseases, Infectious, Soft Tissue Infections

Trial Timeline

Apr 1, 2006 → —

NCT ID
NCT00430937

About Daptomycin + Vancomycin + Teicoplanin

Daptomycin + Vancomycin + Teicoplanin is a phase 3 stage product being developed by Novartis for Skin Diseases, Infectious. The current trial status is terminated. This product is registered under clinical trial identifier NCT00430937. Target conditions include Skin Diseases, Infectious, Soft Tissue Infections.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT00430937Phase 3Terminated

Competing Products

20 competing products in Skin Diseases, Infectious

See all competitors
ProductCompanyStageHype Score
[203Pb]VMT01 + [212Pb]VMT01 + NivolumabPerspective TherapeuticsPhase 1/2
33
[203Pb]VMT01 + [68Ga]VMT02Perspective TherapeuticsPhase 1
25
Mupirocin Calcium Cream, 2% + Bactroban® Cream + Cream vehicle of test productSun PharmaceuticalPhase 1
33
LY3041658 + PlaceboEli LillyPhase 1
33
DSP-9632P 27.5 mg + DSP-9632P 82.5 mg + Placebo + DSP-9632P 55.0 mg + Levodopa formulationSumitomo PharmaPhase 1
33
levofloxacinJohnson & JohnsonPhase 2/3
65
Moisturizer A, F#9155-005Johnson & JohnsonPre-clinical
23
levofloxacinJohnson & JohnsonPhase 3
77
CeftobiproleJohnson & JohnsonPhase 1
33
Natural Killer Cell Therapy + Universal Donor Expanded TGF-beta-imprinted NK CellsJohnson & JohnsonPhase 1
33
LevofloxacinJohnson & JohnsonPhase 3
77
CeftobiproleJohnson & JohnsonPhase 1
33
Levodopa-carbidopa intestinal gelAbbViePhase 3
77
IressaAstraZenecaPhase 2
52
Daptomycin + VancomycinAstraZenecaPhase 3
77
SarizotanMerckPre-clinical
23
Pembrolizumab + EDP1503MerckPhase 2
52
testosterone gel + Comparator: placeboMerckPhase 1
33
LNS8801 + Pembrolizumab + Chemotherapy (dacarbazine or temozolomide) + Immunotherapy (Pembrolizumab) + Immunotherapy (nivolumab and relatlimab) + Immunotherapy (ipilimumab and nivolumab)MerckPhase 2/3
65
Vancomycin + Daptomycin + Semi-Synthetic PenicillinMerckApproved
85

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85